Paradisi Andrea, Bocchino Enrico, Mannino Maria, Gualdi Giulio, D'Amore Alessandra, Traini Daniele Omar, Peris Ketty
Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli-IRCCS, 00168 Rome, Italy.
J Pers Med. 2025 Sep 3;15(9):421. doi: 10.3390/jpm15090421.
Actinic keratosis (AK) is considered the early phase of a squamous cell carcinoma (SCC) and represents one of the most common epithelial skin lesions, with an estimated global prevalence of approximately 14%. An estimated annual risk of progression has been reported with a range from 0 to 0.53%. Although spontaneous regression of individual AK lesions has been described in approximately 23% of cases, the frequent presence of multiple lesions, usually in the broader context of field cancerization, significantly diminishes the likelihood of regression and contributes to a higher cumulative risk of progression to SCC. The aim of the present narrative review was to provide an overview of the current evidence of the most effective available lesion-directed and field-directed treatments for actinic keratoses, on the personalized, combined, or sequential approach, as well as on the emerging therapeutic options.
光化性角化病（AK）被认为是鳞状细胞癌（SCC）的早期阶段，是最常见的上皮性皮肤病变之一，全球估计患病率约为14%。据报道，每年的进展风险估计在0%至0.53%之间。虽然约23%的病例中描述了单个AK病变可自发消退，但通常在广泛的场癌化背景下频繁出现多个病变，显著降低了消退的可能性，并导致进展为SCC的累积风险更高。本叙述性综述的目的是概述目前关于光化性角化病最有效的现有病变导向和场导向治疗的证据，包括个性化、联合或序贯方法，以及新兴的治疗选择。
